

Physician Publications and Presentations

Gynecology Oncology • Kendrick

Publications

Gubbi A, **Kendrick JE**, Finkler NJ. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer. *Expert Rev. Anticancer. Ther.* 2014; 14: 1105-1113.

Kendrick JE IV, Ahmad S, **Holloway RW**. Robotic pelvic and aortic lymphadenectomy for gynecologic malignancies – One approach. In: *Robotic Surgery: Practical Examples in Gynecology*(Kilic SG, Ertan AK, Kose MF, Eds.), de Gruyter Publisher, Berlin, 2014; pp. 221-236.

Alvarez EA, Brady WE, Walker J, Rotmensch J, Zhou XC, **Kendrick JE**, Yamada SD, Schilder JM, Cohn D, Harrison CR, Moore KN, Aghajanian C. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study. *Gynecologic Oncology* 2013; 129: 22-27.

Kendrick JE IV, Ahmad S, Holloway RW. Robotic pelvic and aortic lymphadenectomy for gynecologic malignancies – One approach. In: *Robotic Gynecologic Surgery* (Kilic SG, Ertan K, Kose F, Eds.), European Publisher, First Edition, 2013; In Press.

Brudie LA, Gaia G, Ahmad S, Finkler NJ, Bigsby IV GE, Ghurani GB, **Kendrick IV JE**, Rakowski JA, Groton JH, **Holloway RW**. Peri-operative outcomes of patients with stage IV endometriosis undergoing robotic-assisted laparoscopic surgery. *Journal of Robotic Surgery* 2012; 6: 317-322.

Bevis KS, Straughn JM Jr, **Kendrick JE**, Walsh-Covarrubias J, Kilgore LC. **Morbidity and mortality conference on obstetrics and gynecology: A tool for addressing the 6 core competencies.***Journal of Graduate Medical Education* 2011; 3: 100-103.

Sfakianos GP, Frederick PJ, **Kendrick JE**, Straughn JM, Kilgore LC, Huh WK. Robotic surgery in gynecologic oncology fellowship programs in the USA: A survey of fellows and fellowship directors. *International Journal of Medical Robotics* 2010; 6: 405-412.

Greer HO, Frederick PJ, Falls NM, Tapley EB, Samples KL, Kimball KJ, **Kendrick JE**, Conner MG, Novak L, Straughn JM Jr. Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies. *International Journal of Gynecological Cancer* 2010; 20: 1321-1325.

Leath CA III, Numnum TM, **Kendrick JE IV**, Frederick PJ, Rocconi RP, Conner MG, Straughn JM Jr. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapy. *International Journal of Gynecological Cancer* 2009; 19: 888-891.

Frederick PJ, **Kendrick JE**, Straughn JM Jr, Della Manna DL, Oliver PG, Lin HY, Grizzle WE, Stockard CR, Alvarez RD, Zhou T, LoBuglio AF, Buchsbaum DJ. Effect of TRA-8 anti-death receptor 5 antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. *International Journal of Gynecological Cancer* 2009; 19: 814-819.

Sfakianos GP, Numnum TM, Halverson CB, Panjeti D, **Kendrick JE**, Straughn JM Jr. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. *Gynecologic Oncology* 2009; 114: 424-426.

Wetta LA, Matthews KS, Kemper ML, Whitworth JM, Fain ET, Huh WK, **Kendrick JE**, Straughn JM Jr. The management of cervical intraepithelial neoplasia during pregnancy: Is colposcopy necessary? *Journal of Lower Genital Tract Disease* 2009; 13: 182-185.

Whitworth JM, Matthews KS, Shipman KA, Numnum TM, **Kendrick JE**, Kilgore LC, Straughn JM Jr. The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. *Gynecologic Oncology* 2009; 112: 601-614.